北京招聘

We are seeking an experienced and highly motivated scientist with strong hands-on experience in antibody discovery to join us. A main objective for this candidate will be to independently conduct therapeutic antibody discovery projects using high throughput (HTP) B-cell cloning or hybridoma technology from immunized animals and/or human samples. The candidate should be current with the latest technology developments and be able to propose and implement process improvement technologies to aid reduction in cycle time and improve attrition rates. The candidate will serve as project team leader to coordinate research activities in a multi-disciplinary setting. This will involve data presentation in well-organized written and oral formats at various team, group, and project review meetings. 

Responsibilities

1.      Conduct antibody discovery projects using different approaches to support cell therapy and therapeutic antibody programs.

2.      Serve as project team leader, manage project progress and timeline, and provide regular updates in achieving the specific objectives of the respective research projects.

3.      Work cross-functionally as part of internal multi-disciplinary teams, coordinating lead isolation, optimization and characterization.

Qualifications

1.      PhD with 2-3 years, or MS with 5-7 years of experience in Immunology, Cell Biology, Molecular Biology, or related discipline.

2.      Demonstrated successful experience in antibody research, preferably in an industry setting

3.      Strong scientific understanding of immunology and conceptual and technical expertise in hybridoma and state of the art HTP B-cell cloning and screening technologies.

4.      Expertise with characterization of antibody binding to proteins and cells and bioinformatic analysis of antibody sequences is required. Additional experience with display technology is a strong plus.

5.      Excellent data management, written and presentation skills and a team player. 

传奇生物（NASDAQ: LEGN）是一家处于临床阶段的全球生物制药公司，专注于肿瘤和其他领域的新型细胞疗法的开发。目前，公司在中国、美国、欧洲拥有800多名员工。运用创新的技术手段、全球研发模式、生产策略和专业知识，公司具备强大的潜力为患者开发和制造一流的细胞疗法。传奇生物通过战略合作开发和商业化旗下主导产品西达基奥仑赛（cilta-cel），这是一种靶向BCMA的CAR-T细胞疗法用于治疗多发性***瘤患者，该药物目前正处于注册临床试验阶段。